Aldeyra Therapeutics (ALDX) Total Liabilities (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Total Liabilities for 14 consecutive years, with $9.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 67.46% year-over-year to $9.7 million; the trailing twelve-month figure through Jun 2026 stood at $9.7 million (down 67.46% YoY), and the FY2025 full-year result was $27.8 million, down 17.24% from the prior year.
• Total Liabilities eased to $9.7 million in Q2 2026 per ALDX's latest filing, from $24.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $33.6 million in Q4 2024 and bottomed at $9.7 million in Q2 2026.
• Historically, Total Liabilities has averaged $27.6 million across 5 years, with a median of $28.2 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities surged 50.74% in 2022, then tumbled 67.46% in 2026.
• Over 5 years, Total Liabilities stood at $30.3 million in 2022, then retreated by 5.78% to $28.5 million in 2023, then gained by 17.77% to $33.6 million in 2024, then dropped by 17.24% to $27.8 million in 2025, then slumped by 65.28% to $9.7 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $9.7 million, $24.3 million, and $27.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.